ReviewBiological reviews of the Cambridge Philosophical Society2016
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose.
Review in Biological reviews of the Cambridge Philosophical Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 312 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
312 citing papers in PubMed, 1 synthesis or guideline pooled it, 487 citations in OpenAlex.
- Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review.Nutrients · 2023Pooled it
- Beneficial Effects of Carbohydrate Restriction in Type 2 Diabetes Can Be Traced to Changes in Hepatic Metabolism.The Journal of clinical endocrinology and metabolism · 2025Trial
- Mixed active metabolites of the SNP-6 series of novel compounds mitigate metabolic dysfunction-associated steatohepatitis and fibrosis: promising results from pre-clinical and clinical trials.Journal of translational medicine · 2024Trial
- Trial
- Effects of a low-carbohydrate/high-protein diet on metabolic health in individuals with chronic spinal cord injury: An exploratory analysis of results from a randomized controlled trial.Physiological reports · 2022Trial
- Comparative Analysis of the Effects of Fish Oil and Fenofibrate on Plasma Metabolomic Profiles in Overweight and Obese Individuals.Molecular nutrition & food research · 2022Trial
- Prime editing models the MTARC1 A165T variant in human liver organoids, demonstrating reduced steatosis, inflammation, and fibrosis.Hepatology communications · 2026Article
- Structures of the human sodium-citrate cotransporter NaCT with and without substrates.Structure (London, England : 1993) · 2026Article
- Changes in Glycemic Control and Lipid Profiles Following COVID-19 Infection in Adults with Type 2 Diabetes: A Retrospective Study in Saudi Arabia.Pathogens (Basel, Switzerland) · 2026Article
- Flavonoids for MASLD: Hepatic Lipid Targets, Biopharmaceutic Barriers, and Formulation Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Acute and 28-Day Toxicity Evaluation of New Pleuromutilin Derivative 4g.Journal of applied toxicology : JAT · 2026Article
- Impaired mTOR/SREBP1-Mediated Lipogenesis as a Mechanism of Hepatic Glycogen Accumulation in a Carnivorous Fish Model, Largemouth Bass (Micropterus salmoides).FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Maternal Large Yellow Tea Supplementation Confers Intergenerational Protection Against BPA-Induced Metabolic and Behavioral Disorders in Mice.Metabolites · 2026Article
- Dietary Bile Acid Supplementation Improves Lipid Metabolism and Selected Egg Quality Traits in Late-Phase Laying Hens Fed a High-Fat Diet and Is Associated with Alterations in Gut Microbiota.Animals : an open access journal from MDPI · 2026Article
- Mapping Double-Bond Positional Isomers of Phosphatidylcholines in Zebrafish Using OzMALDI Mass Spectrometry Imaging.Journal of the American Society for Mass Spectrometry · 2026Article
- N6-(2-Hydroxyethyl) Adenosine Alleviates Hepatic Steatosis and Insulin Resistance by Inhibiting JunB+ Adipocytes.Phytotherapy research : PTR · 2026Article
- DGAT2 inhibition in MASH: histologic promise and lipid paradox.Hepatobiliary surgery and nutrition · 2026Article
- Structures of the human sodium-citrate cotransporter NaCT with and without substrates.bioRxiv : the preprint server for biology · 2026Article
- FGF21 and SHBG as Putative Hepatic Axes in Maternal Metabolic Adaptation: A Hypothetical Framework for Postpartum Insulin Sensitivity Restoration.Biomolecules · 2026Review
- Amphibian Skin-Derived Peptides as Emerging Therapeutic Scaffolds for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Pharmaceuticals (Basel, Switzerland) · 2026Review
252 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Hepatic de novo lipogenesis (DNL) is the biochemical process of synthesising fatty acids from acetyl-CoA subunits that are produced from a number of different pathways within the cell, most commonly carbohydrate catabolism. In addition to glucose which most commonly supplies carbon units for DNL, fructose is also a profoundly lipogenic substrate that can drive DNL, important when considering the increasing use of fructose in corn syrup as a sweetener. In the context of disease, DNL is thought to contribute to the pathogenesis of non-alcoholic fatty liver disease, a common condition often associated with the metabolic syndrome and consequent insulin resistance. Whether DNL plays a significant role in the pathogenesis of insulin resistance is yet to be fully elucidated, but it may be that the prevalent products of this synthetic process induce some aspect of hepatic insulin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.